Summary & Overview
HCPCS Level II Q5121: Injection, infliximab-axxq (Avsola), 10 mg
HCPCS Level II code Q5121 denotes injection of infliximab-axxq, the biosimilar Avsola, in 10 mg units. This code identifies a widely used intravenous biologic therapy option for multiple inflammatory and autoimmune diseases and matters nationally for clinicians, payers, and facilities because biosimilar adoption affects drug spend, access to biologic therapies, and billing workflows. Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare.
Readers will find a concise explanation of the code and clinical context, typical sites of service, and payer coverage considerations. The publication summarizes national benchmarks for utilization and reimbursement where available, highlights relevant coding and billing practice implications for infusion services, and outlines areas where policy updates or payer guidance commonly impact claims processing. Data not available in the input are indicated where applicable. The content is intended to inform billing staff, practice managers, and policy analysts about the administrative and clinical framing of HCPCS Level II code Q5121 without offering clinical recommendations.
Billing Code Overview
HCPCS Level II code Q5121 represents an injection of infliximab-axxq, a biosimilar marketed as Avsola, in a 10 mg unit. The service is an intravenous biologic infusion used to treat inflammatory and autoimmune conditions for which infliximab is indicated.
Service Type: Therapeutic infusion (biologic agent administration)
Typical Site of Service: Outpatient infusion centers, hospital outpatient departments, and physician offices equipped for intravenous biologic administration
Clinical & Coding Specifications
Clinical Context
A 52-year-old patient with moderate to severe Crohn disease established on maintenance biologic therapy presents to an outpatient infusion center for scheduled intravenous administration of a biosimilar infliximab product, Q5121 (infliximab-axxq, avsola), 10 mg unit dosing. The visit begins with nursing intake that includes vitals, allergy check, review of recent labs including tuberculosis screening and basic metabolic panel, and verification of premedication needs. The infusion nurse prepares the dose based on the physician’s orders, documents lot number and Q5121 units administered, and attaches applicable modifiers for billing (for example JW for discarded drug or JG for an expired code linkage when required by payor rules). The infusion is delivered via peripheral IV over the institution-standard infusion time (commonly 2 hours for initial doses, may be shorter for maintenance per protocol), with monitoring for infusion reactions. Post-infusion, the patient is observed for adverse events for a specified observation period, discharge instructions are provided, and the administration is coded and billed to the patient’s insurer using Q5121 with appropriate ICD-10 diagnosis linkage (for example inflammatory bowel disease or rheumatoid arthritis) and any required modifiers documenting dosage, wastage, or payer-specific conditions.
Coding Specifications
| Modifier | Description | When to Use |
|---|